Investigator Perspectives

Investigator Perspectives

Targeted Oncology presents Investigator Perspectives, a video series featuring key opinion leaders discussing how to approach and manage patients with different tumor types.


Ruxolitinib for Steroid-Refractory GVHD: The REACH Trials

July 21st 2021

In this Investigator Perspectives, Yi-Bin Chen, MD discusses the difference between acute and chronic graft versus host disease, the initial therapeutic management of these diseases, and the newly-approved agents for steroid-refractory disease. He also provides his insights regarding future directions and unmet needs for steroid-refractory GVHD.

Phase 3 REFLECT Trial in Patients with Unresectable Hepatocellular Carcinoma

July 20th 2021

An expert in hematology-oncology provides key insights into treatment considerations for patients with hepatocellular carcinoma and reviews safety and efficacy data from the phase 3 REFLECT Trial of lenvatinib for patients with unresectable disease.

Radioligand Therapy 177Lu-PSMA-617 in Progressive PSMA-positive mCRPC

June 30th 2021

Andrew J. Armstrong, MD, MSc, evaluates the use of LuPSMA therapy in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

The Phase 3 CLEAR Trial: Lenvatinib Plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma

June 29th 2021

Robert J. Motzer, MD, gives a comprehensive background and analysis on the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus versus sunitinib in the treatment of advanced renal cell carcinoma.

AMEERA-5: A Randomized, Double-Blind Phase III Study of Amcenestrant + Palbociclib vs Letrozole + Palbociclib for Previously Untreated ER+/HER2- Advanced Breast Cancer

June 28th 2021

Sara Hurvitz, MD, reviews the implications of the AMEERA-5 trial, a randomized, double-blind phase III study of amcenestrant + palbociclib vs letrozole + palbociclib in the treatment of ER+/HER2- advanced breast cancer.

The SELECT Trial and Differentiated Thyroid Cancer

June 25th 2021

Lori Wirth, MD provides an overview of differentiated thyroid cancer and reviews key data from the SELECT trial examining the use of lenvatinib.

CAR T Therapy and Durable Responses in MCL

April 20th 2021

Frederick Locke, MD, discusses treatment options for patients with mantle cell lymphoma and the use of CAR T-cell therapy in clinics.

Examining the Role of Frontline BTKi Monotherapy in CLL

March 29th 2021

Expert perspectives on the use of frontline BTKi (Bruton's tyrosine kinase inhibitors) monotherapy in the treatment of chronic lymphocytic leukemia (CLL).

Belantamab Mafodotin in Clinical Practice for Heavily Pretreated MM

March 29th 2021

Sagar Lonial, MD, FACP, discusses the FDA’s recent accelerated approval of belantamab mafodotin for patients with triple-class refractory multiple myeloma (MM) and considers best practices for managing ocular toxicities.

Are Combinations the Answer in Metastatic RCC?

March 29th 2021

Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.